Saif M Wasif, Roy Shailja, Ledbetter Leslie, Madison Jennifer, Syrigos Kostas
Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA.
World J Gastroenterol. 2007 Oct 21;13(39):5277-81. doi: 10.3748/wjg.v13.i39.5277.
Hypersensitivity reactions (HSR) to oxaliplatin in patients with colorectal cancer include facial flushing, erythema, pruritus, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. We report a patient with fever as the sole manifestation of initial HSR, review the literature and discuss the management of HSR. A 57-year-old female with T3N2M0 rectal adenocarcinoma received modified FOLFOX-6. She tolerated the first 8 cycles without any toxicities except grade 1 peripheral neuropathy and nausea. During 9th and 10th infusions, she developed fever to a maximum of 38.3 centigrade with stable hemodynamic status despite medications. During 11th infusion, she developed grade 3 HSR consisting of symptomatic bronchospasm, hypotension, nausea, vomiting, cough, and fever. On examination, she was pale, cyanotic, with a temperature of 38.8 centigrade, BP dropped to 95/43 mm Hg, pulse of 116/min and O(2) saturation of 88%-91%. She was hospitalized for management and recovered in 24 h. Fever alone is not a usual symptom of oxaliplatin HSR. It may be indicative that the patient may develop serious reactions subsequently, as did our patient who developed hypotension with the third challenge. Treatment and prevention consists of slowing the infusion rate, use of steroids and antagonists of Type 1 and 2 histamine receptor antagonists, whereas desensitization could help to provide the small number of patients who experience severe HSR with the ability to further receive an effective therapy for their colorectal cancer.
结直肠癌患者对奥沙利铂的超敏反应(HSR)包括面部潮红、红斑、瘙痒、发热、心动过速、呼吸困难、舌肿胀、皮疹/荨麻疹、头痛、寒战、虚弱、呕吐、烧灼感、头晕和水肿。我们报告一例以发热为初始HSR唯一表现的患者,回顾文献并讨论HSR的管理。一名57岁女性,患有T3N2M0直肠腺癌,接受改良FOLFOX-6方案治疗。她耐受了前8个周期,除1级周围神经病变和恶心外无任何毒性反应。在第9次和第10次输注期间,尽管用药,她仍出现发热,最高体温达38.3摄氏度,血流动力学状态稳定。在第11次输注期间,她出现3级HSR,表现为症状性支气管痉挛、低血压、恶心、呕吐、咳嗽和发热。检查时,她面色苍白、发绀,体温38.8摄氏度,血压降至95/43 mmHg,脉搏116次/分钟,氧饱和度88%-91%。她住院治疗,24小时后康复。单独发热并非奥沙利铂HSR的常见症状。这可能表明患者随后可能发生严重反应,就像我们的患者在第三次输注时出现低血压一样。治疗和预防包括减慢输注速度、使用类固醇以及1型和2型组胺受体拮抗剂,而脱敏疗法有助于为少数经历严重HSR的患者提供继续接受结直肠癌有效治疗的能力。